Objective: To investigate the eect of L-dopa on the PLM/h index of spinal cord injured subjects. Setting: SaÄ o Paulo, Brazil. Methods: Thirteen male volunteers with spinal cord section between T7 ± T12, and mean age of 31.6+8.3 years participated in the study. L-dopa or placebo were administered for 30 days, 1 h before the volunteers went to sleep, in a double blind, crossover design. Polysomnographic recordings were performed on ten occasions: Phase 1: Basal night, following an adaptation night at the sleep laboratory; phase 2: after 1, 7, 21 and 30 days of L-dopa administration; phase 3: ®rst night of L-dopa or placebo withdrawal; phase IV: 1, 7, 21 and 30 days after placebo ingestion. Results: The index of PLM/h on the ®rst night of L-dopa or placebo withdrawal (phase III) was lower than on both the basal night and the ®rst night of L-dopa treatment. At the time of polysomnographic analysis, volunteers were divided into two groups: index of PLM/h below ®ve and those whose index was above ®ve. Comparison between L-dopa and placebo treatments revealed that only those volunteers with an index above ®ve revealed a reduction in PLM in L-dopa. Conclusion: These results indicate that despite the spinal cord lesions, L-dopa treatment is capable of minimizing PLM during sleep.
Introduction
The restless legs syndrome (RLS) was originally described in the general population by Ekbom. 1 Later, an association between RLS and periodic leg movements (PLM) was reported. 2, 21 These disturbances may result in decreased sleep eciency and sleep quality. A relation between dopaminergic de®cit and PLM/RLS 3 as well as a reduction of dopaminergic D 2 receptors in the basal ganglia of patients with PLM has been described. 4 Several studies have reported favourable results of treatment of PLM with dopaminergic agonists. 5 ± 7 There is, however, a lack of consensus regarding dosage and length of administration of these drugs with therapeutic doses ranging between 100 and 250 mg of L-dopa.
Recently, a high incidence of PLM and RLS in subjects with spinal cord lesions have been reported, 8 ± 12 allowing the possibility of identifying the origin of these abnormal movements. These subjects spontaneously report sleep problems, and also even mention the need to be tied to the bed so as to avoid falling on the¯oor due to the frequency of lower limb movements during sleep. 9 Moreover, reduction of the incidence of PLM and RLS following acute physical activity in these patients may be helpful for the identi®cation of the mechanisms underlying PLM and RLS. 10, 13 Thus, it is possible that the reduction of limb movements may stem from endorphin secretion induced by physical activity, 14 since treatment with opiates often results in a reduction of PLM and RLS. 3 In addition, there is an important positive correlation between PLM and K complexes in spinal cord injured 10, 11 and non-paraplegic subjects. 3 To our knowledge, there is no study of PLM in spinal cord lesioned subjects treated with dopaminergic agonists.
It is known that dopamine plays an important role in motor activity in general. Demonstrably, dopaminergic agonists induce a decrease in motor activity. Tu®k 15 highlighted the reduction in motor activity following administration of dopaminergic agonists in REM sleep deprived rats. Andrade 16 reported the role played by dopamine on the pathophysiology of abnormal movements in Parkinsonian patients. Dopaminergic agonists have since been used in the treatment of movement disorders. Maitra 17 observed the involvement of the spinal cord in the pathophysiology of extrapyramidal motor disorders. There are motor nerve terminals containing muscarinic as well as inhibitory dopaminergic receptors that in¯uence acetylcholine release at the spinal cord level. 18 In order to study the inhibitory in¯uence of the dopaminergic system on spinal cholinergic transmission, Maitra 17 used a monosynaptic excitatory pathway from the collateral a motor axon of the Renshaw cells using apomorphine (a dopaminergic agonist) and sulpiride (a D 2 dopaminergic antagonist). Based on their ®ndings, the authors concluded that dopamine inhibited motor activity and in¯uenced central acetylcholine transmission. We may conclude that dopaminergic receptors are clearly involved in the central modulation of cholinergic transmission originating in the collateral a motor axon of the Renshaw cells.
We therefore decided to test the hypothesis that abnormal movements in paraplegic subjects (PLM) have a similar origin to PLM found in non-paraplegic subjects. To this end, we treated such patients with Ldopa (200 mg) associated to 50 mg to benzerazide (peripheral dopaminergic antagonist) as an attempt to observe only the central eects of this medication on PLM/h indices in this speci®c population.
Methods
Thirteen male volunteers (mean age=31.6+8.3 years), with complete spinal cord lesion, between T7 and T12, were selected following contact through associations for the disabled in the state of SaÄ o Paulo, Brazil. The subjects were submitted to clinical/neurological and neuroimaging evaluation to con®rm the diagnosis.
L-Dopa (200 mg), in assocation with benzerazide chloride (50 mg), or placebo was administered for 30 days, 1 h prior to sleep time. This period of drug administration was followed by a 15-day period of washout, in a double-blind, crossover design. The subjects were divided into two groups, Group 1 receiving placebo whilst Group 2 were administered L-dopa (200 mg) associated to Benzerazide (50 mg). Polysomnographic (PSG) data (total of 130 recordings) were obtained in the following manner: Phase 1A: basal PSG; Phase 2A: PSG in 1, 7, 21 and 30 days; Phase 3A: PSG day 1 after drug or placebo withdrawal; Phase 1B: after 15 days of washout (second basal PSG for readaptation); Phase 2B: PSG 1, 7, 21 and 30 days; Phase 3B: PSG day 1 after drug or placebo withdrawal. In accordance with the crossover design, all volunteers received L-dopa (200 mg) associated to benzerazide (50 mg) and placebo.
Volunteers slept on two consecutive nights for basal evaluation in which the ®rst night served as an adaptation night. Polysomnographic recordings were taken on the second night.
There was a similar second adaptation (readaptation) in the period preceding phase IIB as volunteers had spent 15 days away from the environment of our sleep laboratory.
Polysomnography was performed according to Rechtschaen and Kales 19 and electrode placement was carried out according to the 10 ± 20 system. 20 Recordings were obtained using the Oxford/Medilog system (12 channels), with three channels for EEG, three channels for EMG (two on the legs and one on the chin), two channels for EOG, one channel for ECG, one channel for air¯ow, and two channels for abdominal and thoracic respiratory movements.
According to criteria established by ASDA, pathological indices for PLM are above ®ve movements per hour, in non paraplegic patients. To this end, in order to analyze our results, we decided to split the subjects into two groups. (Group 1) those with less than ®ve movements per hour; (Group 2) those displaying more than ®ve movements per hour. 21 The Kolmorogov-Smirnov test was used to evaluate the normal distribution of the samples. Data was subsequently analyzed using the Kruskal-Wallis test, followed by the Friedman ANOVA and the Kendall coecient of concordance test to compare the sleep parameters of groups 1 (45 PLM/h) and 2 (45 PLM/ h) under drug and placebo treatments. The Wilcoxon matched pair test was used to compare withdrawal night (phases 3A+B) with basal night (phases 1A+B), with ®rst night of drug administration (phase 2A+B), and with the ®rst night of placebo administration. Comparison of total arousal among recordings of basal 1st, 7th, 21st, 30th nights of L-dopa treatment was performed by the paired Student's t-test. Comparison among treatment nights and the corresponding placebo nights was performed by the Student's t-test for independent samples. Arousal was considered when the event was longer than 3 s, according to the criteria established by the American Sleep Disorders Association. 22 Volunteers followed a speci®ed dietary regime on the lines recommended for the entire duration of the study. 23 
Results
Despite a progressive decline of PLM absolute values throughout the period of L-dopa treatment, the reduction of abnormal movements of the lower limbs during sleep was not statistically signi®cant in the group as a whole ( Table 1) .
The Wilcoxon matched pairs test was used to compare data from phase 3 (withdrawal) and data from phases 1 (basal) and 2 (®rst night of L-dopa administration). The analysis highlighted a signi®cant reduction of the PLM/h index (phase 36phase 1; P50.01 and phase 36phase 2; P50.03).
When both groups 1 (index of PLM/h below ®ve) and 2 (index of PLM/h above ®ve) were analyzed separately, no statistical dierence between phases 2 (L-dopa) and 3 (withdrawal) was observed for group 1. However, Group 2 revealed a signi®cant reduction of abnormal lower limb movements during L-dopa administration (P50.006).
There were no statistical dierences on total number of arousals, despite a PLM reduction induced by treatment with L-dopa. In regard to the apnea/ hypopnea index, our sample presented indices within the normal range.
Discussion
Lesions or injury of the spinal cord at the cervical, thoracic or lumbar levels determine paraplegic or tetraplegic conditions. Subjects bearing this kind of lesion exhibit several sequelae such as decreased motor activity, muscle atrophy, reduction and impairment of metabolic and cardiac activity, as well as the decline of physical capacity. 23 In spinal cord injured (at the level of T7 ± T12) subjects, abnormal lower limb movements (PLM) could be in¯uenced by dopamine at the spinal level. 24, 25 Consequently, the dopaminergic inhibitory role on abnormal motor activity is impaired by the spinal cord lesion, and might be restored by treatment with L-dopa associated with benzerazide as suggested by the above results. Another possible explanation for the lack of reduction on the number of arousals might be the occurrence of respiratory events during sleep. Nonetheless, our volunteers presented an apnea/ hypopnea index within normal values, detected by the air¯ow technique. Still, it is not possible to reject the occurrence of altered upper airway resistance, which might have maintained the high levels of arousal. These data may also suggest that the arousal mechanism associated with abnormal movements is impaired in subjects bearing spinal cord lesion; with the lack of sensitivity below the level of the lesion the stimulus generated by the abnormal movements would not be perceived and would not result in arousal. It is not easy to explain how the transmission of an excitatory stimulus (highly likely to be generated in the basal ganglia) might produce movements below the level of a complete spinal cord injury. Even more surprising are the volunteers' responses to the treatment L-dopa+benzerazide. One hypothesis to account for this imbalance may involve the maintenance of a monosynaptic pathway, 17 capable of regulating the transmission of dopaminergic stimuli. Dopamine, by stimulating dopaminergic D 2 receptors, might inhibit central cholinergic transmission yielding a neurochemical balance (excitatory/inhibitory) which would prevent the occurrence of such abnormal movements. In our group of paraplegic subjects with complete spinal cord lesions, this monosynaptic pathway may be compromised permitting the appearance of such abnormal movements (PLM). Exogenous L-dopa, seemingly, would reinstate this balance, reducing abnormal movements of the lower limbs.
In the present study, L-dopa was administered 1 h before bed time, which might have resulted in a possible drop in the compound's concentration during the ®nal third of the night, thus reducing the drug's ecacy on the PLM index. The use of a controlledrelease L-dopa could be a useful strategy in future studies, in order to reduce this problem. 
